Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

The effectiveness of a low-intensity problem-solving intervention for common adolescent mental health problems in New Delhi, India: protocol for a school-based, individually randomized controlled trial with an embedded stepped-wedge, cluster randomized controlled recruitment trial.

Parikh R, Michelson D, Malik K, Shinde S, Weiss HA, Hoogendoorn A, Ruwaard J, Krishna M, Sharma R, Bhat B, Sahu R, Mathur S, Sudhir P, King M, Cuijpers P, Chorpita BF, Fairburn CG, Patel V.

Trials. 2019 Sep 18;20(1):568. doi: 10.1186/s13063-019-3573-3.

2.

Priorities and preferences for school-based mental health services in India: a multi-stakeholder study with adolescents, parents, school staff, and mental health providers.

Parikh R, Michelson D, Sapru M, Sahu R, Singh A, Cuijpers P, Patel V.

Glob Ment Health (Camb). 2019 Aug 19;6:e18. doi: 10.1017/gmh.2019.16. eCollection 2019.

3.

Design and Development of the "POD Adventures" Smartphone Game: A Blended Problem-Solving Intervention for Adolescent Mental Health in India.

Gonsalves PP, Hodgson ES, Kumar A, Aurora T, Chandak Y, Sharma R, Michelson D, Patel V.

Front Public Health. 2019 Aug 23;7:238. doi: 10.3389/fpubh.2019.00238. eCollection 2019.

4.

Development of a transdiagnostic, low-intensity, psychological intervention for common adolescent mental health problems in Indian secondary schools.

Michelson D, Malik K, Krishna M, Sharma R, Mathur S, Bhat B, Parikh R, Roy K, Joshi A, Sahu R, Chilhate B, Boustani M, Cuijpers P, Chorpita B, Fairburn CG, Patel V.

Behav Res Ther. 2019 Jul 30:103439. doi: 10.1016/j.brat.2019.103439. [Epub ahead of print]

5.

Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Farez MF, Correale J, Armstrong MJ, Rae-Grant A, Gloss D, Donley D, Holler-Managan Y, Kachuck NJ, Jeffery D, Beilman M, Gronseth G, Michelson D, Lee E, Cox J, Getchius T, Sejvar J, Narayanaswami P.

Neurology. 2019 Sep 24;93(13):584-594. doi: 10.1212/WNL.0000000000008157. Epub 2019 Aug 28.

PMID:
31462584
6.

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.

Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D.

Alzheimers Res Ther. 2019 Aug 7;11(1):68. doi: 10.1186/s13195-019-0520-1.

7.

What are young Indians saying about mental health? A content analysis of blogs on the It's Ok To Talk website.

Gonsalves PP, Hodgson ES, Michelson D, Pal S, Naslund J, Sharma R, Patel V.

BMJ Open. 2019 Jun 22;9(6):e028244. doi: 10.1136/bmjopen-2018-028244.

8.

Assessing social recovery of vulnerable youth in global mental health settings: a pilot study of clinical research tools in Malaysia.

Berry C, Othman E, Tan JC, Gee B, Byrne RE, Hodgekins J, Michelson D, Ng ALO, Marsh NV, Coker S, Fowler D.

BMC Psychiatry. 2019 Jun 20;19(1):188. doi: 10.1186/s12888-019-2164-x.

9.

"It is like a mind attack": stress and coping among urban school-going adolescents in India.

Parikh R, Sapru M, Krishna M, Cuijpers P, Patel V, Michelson D.

BMC Psychol. 2019 May 28;7(1):31. doi: 10.1186/s40359-019-0306-z.

10.

Views of young people in Malaysia on mental health, help-seeking and unusual psychological experiences.

Berry C, Michelson D, Othman E, Tan JC, Gee B, Hodgekins J, Byrne RE, Ng ALO, Marsh NV, Coker S, Fowler D.

Early Interv Psychiatry. 2019 May 21. doi: 10.1111/eip.12832. [Epub ahead of print]

PMID:
31111672
11.

Feasibility randomized controlled trial of a one-day CBT workshop ('DISCOVER') for 15- to 18-year-olds with anxiety and/or depression in clinic settings.

Loucas CE, Sclare I, Stahl D, Michelson D.

Behav Cogn Psychother. 2019 May 20:1-18. doi: 10.1017/S1352465819000286. [Epub ahead of print]

PMID:
31106728
12.

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.

PMID:
30970186
13.

Portable System for Monitoring and Controlling Driver Behavior and the Use of a Mobile Phone While Driving.

Khandakar A, Chowdhury MEH, Ahmed R, Dhib A, Mohammed M, Al-Emadi NAMA, Michelson D.

Sensors (Basel). 2019 Mar 31;19(7). pii: E1563. doi: 10.3390/s19071563.

14.

School-based early intervention for anxiety and depression in older adolescents: A feasibility randomised controlled trial of a self-referral stress management workshop programme ("DISCOVER").

Brown JSL, Blackshaw E, Stahl D, Fennelly L, McKeague L, Sclare I, Michelson D.

J Adolesc. 2019 Feb;71:150-161. doi: 10.1016/j.adolescence.2018.11.009. Epub 2019 Feb 7.

PMID:
30738219
15.

Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.

Herring WJ, Connor KM, Snyder E, Snavely DB, Morin CM, Lines C, Michelson D.

Sleep Med. 2019 Apr;56:219-223. doi: 10.1016/j.sleep.2018.09.010. Epub 2018 Oct 2.

PMID:
30522875
16.

Experimental study of the turbulence effect on underwater optical wireless communications.

Vali Z, Gholami A, Ghassemlooy Z, Omoomi M, Michelson DG.

Appl Opt. 2018 Oct 1;57(28):8314-8319. doi: 10.1364/AO.57.008314.

PMID:
30461783
17.

Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.

Herring WJ, Roth T, Krystal AD, Michelson D.

J Sleep Res. 2019 Apr;28(2):e12782. doi: 10.1111/jsr.12782. Epub 2018 Oct 18. Review.

PMID:
30338596
18.

Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Michelson D, Ciafaloni E, Ashwal S, Lewis E, Narayanaswami P, Oskoui M, Armstrong MJ.

Neurology. 2018 Nov 13;91(20):923-933. doi: 10.1212/WNL.0000000000006502. Epub 2018 Oct 12.

PMID:
30315070
19.

Stigma related to targeted school-based mental health interventions: A systematic review of qualitative evidence.

Gronholm PC, Nye E, Michelson D.

J Affect Disord. 2018 Nov;240:17-26. doi: 10.1016/j.jad.2018.07.023. Epub 2018 Jul 10.

20.

Child Neurology: Siblings with infantile epilepsy and developmental delay: A circuitous path to genomic diagnosis.

Liu Y, Michelson D, Clark R, Gold JA.

Neurology. 2018 Jul 17;91(3):143-147. doi: 10.1212/WNL.0000000000005815.

PMID:
30012655
21.

What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.

Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B.

J Prev Alzheimers Dis. 2018;5(3):171-174. doi: 10.14283/jpad.2018.23.

PMID:
29972209
22.

Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.

Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, Leibensperger H, Snow-Adami L, McMahon KB, Egan M, Michelson D.

Alzheimers Dement (N Y). 2018 Apr 26;4:173-181. doi: 10.1016/j.trci.2018.03.004. eCollection 2018.

23.

Users' experiences of trauma-focused cognitive behavioural therapy for children and adolescents: a systematic review and metasynthesis of qualitative research.

Neelakantan L, Hetrick S, Michelson D.

Eur Child Adolesc Psychiatry. 2019 Jul;28(7):877-897. doi: 10.1007/s00787-018-1150-z. Epub 2018 May 25.

24.
25.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.

26.

Modeling turbulence in underwater wireless optical communications based on Monte Carlo simulation.

Vali Z, Gholami A, Ghassemlooy Z, Michelson DG, Omoomi M, Noori H.

J Opt Soc Am A Opt Image Sci Vis. 2017 Jul 1;34(7):1187-1193. doi: 10.1364/JOSAA.34.001187.

PMID:
29036128
27.

How Does Homelessness Affect Parenting Behaviour? A Systematic Critical Review and Thematic Synthesis of Qualitative Research.

Bradley C, McGowan J, Michelson D.

Clin Child Fam Psychol Rev. 2018 Mar;21(1):94-108. doi: 10.1007/s10567-017-0244-3.

PMID:
28932919
28.

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.

Connor KM, Ceesay P, Hutzelmann J, Snavely D, Krystal AD, Trivedi MH, Thase M, Lines C, Herring WJ, Michelson D.

Int J Neuropsychopharmacol. 2017 Aug 1;20(8):613-618. doi: 10.1093/ijnp/pyx033.

29.

Acute Postviral Encephalopathy: Pathologic and Radiologic Correlation in an Atypical Case.

Achiriloaie A, Michelson D, Lei L, Denham L, Oberg K, Raghavan R.

Child Neurol Open. 2016 Jul 21;3:2329048X16658845. doi: 10.1177/2329048X16658845. eCollection 2016 Jan-Dec.

30.

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.

Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ; Preladenant Early Parkinson Disease Study Group.

Neurology. 2017 Jun 6;88(23):2198-2206. doi: 10.1212/WNL.0000000000004003. Epub 2017 May 10.

PMID:
28490648
31.

Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant.

Joseph Herring W, Ge JY, Jackson S, Assaid C, Connor KM, Michelson D.

Clin J Pain. 2018 Jan;34(1):37-43. doi: 10.1097/AJP.0000000000000503.

PMID:
28448426
32.

Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.

Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D.

Am J Geriatr Psychiatry. 2017 Jul;25(7):791-802. doi: 10.1016/j.jagp.2017.03.004. Epub 2017 Mar 8.

PMID:
28427826
33.

Commentary: Distillation and element-based design of psychological treatments in global mental health - a commentary on Brown et al. (2017).

Michelson D, Patel V.

J Child Psychol Psychiatry. 2017 Apr;58(4):525-527. doi: 10.1111/jcpp.12714.

PMID:
28346758
34.

Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.

Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D.

Psychopharmacology (Berl). 2017 Jun;234(11):1703-1711. doi: 10.1007/s00213-017-4573-1. Epub 2017 Mar 7.

PMID:
28265715
35.

Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.

Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D.

J Clin Sleep Med. 2016 Sep 15;12(9):1215-25. doi: 10.5664/jcsm.6116.

36.

Young voices in mental health care: Exploring children's and adolescents' service experiences and preferences.

Persson S, Hagquist C, Michelson D.

Clin Child Psychol Psychiatry. 2017 Jan;22(1):140-151. doi: 10.1177/1359104516656722. Epub 2016 Jul 26.

PMID:
27368712
37.

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.

Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D.

Cephalalgia. 2016 Aug;36(9):887-98. doi: 10.1177/0333102416653233. Epub 2016 Jun 6.

PMID:
27269043
38.

Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.

Snyder E, Ma J, Svetnik V, Connor KM, Lines C, Michelson D, Herring WJ.

Sleep Med. 2016 Mar;19:93-100. doi: 10.1016/j.sleep.2015.10.007. Epub 2015 Nov 10.

PMID:
27198953
39.

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.

Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ.

Int J Neuropsychopharmacol. 2016 Aug 12;19(8). pii: pyw022. doi: 10.1093/ijnp/pyw022. Print 2016 Aug.

40.

Early intervention for depression and anxiety in 16-18-year-olds: Protocol for a feasibility cluster randomised controlled trial of open-access psychological workshops in schools (DISCOVER).

Michelson D, Sclare I, Stahl D, Morant N, Bonin EM, Brown JS.

Contemp Clin Trials. 2016 May;48:52-8. doi: 10.1016/j.cct.2016.02.003. Epub 2016 Feb 12.

PMID:
26883283
41.

At a Crossroads: A Perspective on Drug Development for Alzheimer's Disease in 2016.

Michelson D, Egan M.

J Prev Alzheimers Dis. 2016;3(4):181-184. doi: 10.14283/jpad.2016.106. No abstract available.

PMID:
29199317
42.

Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.

Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D.

JAMA Neurol. 2015 Dec;72(12):1491-500. doi: 10.1001/jamaneurol.2015.2268.

PMID:
26523919
43.

Chronic administration of anticonvulsants but not antidepressants impairs bone strength: clinical implications.

Gold PW, Pavlatou MG, Michelson D, Mouro CM, Kling MA, Wong ML, Licinio J, Goldstein SA.

Transl Psychiatry. 2015 Jun 2;5:e576. doi: 10.1038/tp.2015.38.

44.

Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine.

Ho TW, Ho AP, Ge YJ, Assaid C, Gottwald R, MacGregor EA, Mannix LK, van Oosterhout WP, Koppenhaver J, Lines C, Ferrari MD, Michelson D.

Cephalalgia. 2016 Feb;36(2):148-61. doi: 10.1177/0333102415584308. Epub 2015 Apr 29.

PMID:
25926620
45.

Looking at variation through a quality lens.

Allegretto S, Michelson D.

Healthc Financ Manage. 2014 Dec;68(12):42-9.

PMID:
25647928
46.

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D.

Biol Psychiatry. 2016 Jan 15;79(2):136-48. doi: 10.1016/j.biopsych.2014.10.003. Epub 2014 Oct 23.

PMID:
25526970
47.

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention.

Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D.

Neurology. 2014 Sep 9;83(11):958-66. doi: 10.1212/WNL.0000000000000771. Epub 2014 Aug 8.

PMID:
25107879
48.

Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis.

Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, Michelson D.

Cephalalgia. 2015 Apr;35(5):379-88. doi: 10.1177/0333102414544979. Epub 2014 Aug 8.

PMID:
25106663
49.

'Living with Teenagers': feasibility study of a peer-led parenting intervention for socially disadvantaged families with adolescent children.

Michelson D, Ben-Zion I, James AI, Draper L, Penney C, Day C.

Arch Dis Child. 2014 Aug;99(8):731-7. doi: 10.1136/archdischild-2013-304936. Epub 2014 Apr 23.

PMID:
24759649
50.

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ.

Lancet Neurol. 2014 May;13(5):461-71. doi: 10.1016/S1474-4422(14)70053-5. Epub 2014 Mar 27.

PMID:
24680372

Supplemental Content

Loading ...
Support Center